Rethinking Clinical Trials

MARCH 18, 2025

In a cost-effectiveness analysis using data from the ABATE Infection trial, a strategy of chlorhexidine bathing and nasal decolonization targeted to hospitalized adults with medical devices in nonintensive care unit (ICU) settings was cost-effective in reducing hospital-acquired infections. The study results were published this month in JAMA Network Open.

Allergies 147

Allergies Trials Clinical Trials Clinical Trials 147

Pharmaceutical Technology

MARCH 20, 2025

OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

Antibody 288

Antibody 288

Bio Pharma Dive

MARCH 18, 2025

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.

Drugs 269

Drugs 269

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 19, 2025

Do ice baths live up to the hype? (Diana Light/Unsplash) Ice baths have become increasingly popular over the past few years. Fitness enthusiasts and casual exercisers around the world are embracing this trend that was once reserved for elite athletes. Ice baths (also known as “cold water immersion“) are exactly what they sound like.

Clinical Trials 244

Clinical Trials Clinical Trials Trials 244

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Rethinking Clinical Trials

MARCH 19, 2025

Dr. Alexander “AJ” Blood In this Friday’s PCT Grand Rounds, Alexander J. “AJ” Blood of Harvard Medical School and Brigham and Women’s Hospital will present “Generative Artificial Intelligence in Clinical Trials: A Driver of Efficiency and Democratization of Care.” The Grand Rounds session will be held on Friday, March 21, 2025, at 1:00 pm eastern.

Clinical Trials 200

Clinical Trials Clinical Trials Trials Medicine 200

Pharmaceutical Technology

MARCH 18, 2025

AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latters ALT-B4 platform technology.

280

280

XTalks

MARCH 19, 2025

Join us as we celebrate a major milestone the 200th episode of the Xtalks Life Science Podcast! From groundbreaking biotech innovations to exclusive interviews with life science industry innovators and leaders, we’ve covered it all. Thank you for tuning in each week! We look forward to continuing to bring the latest and greatest across the pharma, biotech and medical industries!

Life Science 110

Life Science Clinical Development Development Research 110

Rethinking Clinical Trials

MARCH 20, 2025

Dr. Sara Singer, principal investigator for iPATH Researchers from iPATH, an NIH Collaboratory Trial, described key considerations for integrating artificial intelligence tools into analyses of qualitative data. The report was posted this month on the AcademyHealth Blog. The iPATH trial, led by principal investigator Sara Singer at Stanford University, will test the implementation of a practice transformation strategy for type 2 diabetes in federally qualified health centers in California, Massa

Clinical Trials 147

Clinical Trials Clinical Trials Trials Research 147

Pharmaceutical Technology

MARCH 21, 2025

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

FDA Approval 261

FDA Approval 261

Bio Pharma Dive

MARCH 17, 2025

Discover NGS for GxP compliance with full audit trails, operational control and robust data security.

Compliance 246

Compliance 246

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Drug Patent Watch

MARCH 18, 2025

Exploring the Russian Pharma Industry: Key Players and Innovations As we continue to navigate the complexities of the global pharmaceutical landscape, it's essential to stay informed about emerging markets and trends. Today, I want to take you on a journey to Russia, a country with a rich history of pharmaceutical innovation and a growing presence in the industry.

Marketing 96

Marketing Production Development Medicine 96

Rethinking Clinical Trials

MARCH 19, 2025

Speaker Sean Mann Senior Policy Analyst RAND Corporation Slides Keywords Development Economics; Spillover; Bias; Pragmatic Clinical Trials Key Points Individually randomized, parallel-group embedded pragmatic trials randomly assign patients to a new healthcare intervention or to a control group that receives some form of usual care.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Development 100

Pharmaceutical Technology

MARCH 20, 2025

Pfizer has divested its residual shareholding in Haleon, representing 7.3% of the company's share capital, for a total of $3.3bn.

255

255

Bio Pharma Dive

MARCH 17, 2025

With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving the impossible.

246

246

Advertisement

Clinical Supply

Drug Patent Watch

MARCH 19, 2025

Unlocking Strategic Investment Opportunities in the Pharmaceutical Industry As we navigate the ever-evolving landscape of the pharmaceutical industry, one thing remains constant: the expiration of patents on blockbuster medications. These expirations can have a significant impact on the market, creating opportunities for strategic investment and growth.

Drugs 96

Drugs Marketing Manufacturing Development 96

CTTI (Clinical Trials Transformation Initiative)

MARCH 19, 2025

A new publication from the FDA Oncology Center of Excellence (OCE) and the Clinical Trials Transformation Initiative (CTTI), published in the Clinical Cancer Research journal, provides important insights into how decentralized clinical trial (DCT) elements were used in cancer trials leading to FDA approval during the COVID-19 pandemic. DCT elementssuch as remote monitoring, telemedicine, and home delivery of investigational products were widely used in cancer trials to maintain patient safety an

Clinical Trials 75

Clinical Trials Clinical Trials Trials FDA Approval 75

Pharmaceutical Technology

MARCH 21, 2025

J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years.

Pharma Companies 250

Pharma Companies 250

Bio Pharma Dive

MARCH 21, 2025

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

Manufacturing 219

Manufacturing 219

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Drug Patent Watch

MARCH 20, 2025

Unlock the Full Potential of Your Pharmaceutical Product: The Power of a CDMO As a pharmaceutical professional, you're constantly looking for ways to bring innovative products to market faster and more efficiently. One key strategy that can help you achieve this goal is partnering with a Contract Development and Manufacturing Organization (CDMO). But what exactly is a CDMO, and how can it benefit your business?

Production 90

Production Manufacturing Marketing Development 90

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 20, 2025

After a long, stressful day at work, or when pressed for time, the temptation to have a quick, satisfying snack like crisps or a chocolate bar can be strong.

Development 195

Development Research Clinical Trials Clinical Trials 195

Pharmaceutical Technology

MARCH 21, 2025

Menarini Group has announced a partnership with VisualDx to enhance the diagnosis of individuals with BPDCN.

250

250

Bio Pharma Dive

MARCH 18, 2025

The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.

Gene Editing 222

Gene Editing Gene Research 222

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

MARCH 17, 2025

The Hidden Costs of Drug Patent Litigation: How to Stay Ahead of the Game As a pharmaceutical professional, you're no stranger to the complexities of drug patent litigation. The stakes are high, and the costs can be astronomical. But what if I told you that there's a way to manage these costs and stay ahead of the game? In today's fast-paced pharmaceutical landscape, patent litigation is an inevitable reality.

Drugs 96

Drugs Development 96

Drug Channels

MARCH 21, 2025

Todays guest post comes from Greg Skalicky, President of EVERSANA. Greg discusses some of the challenges manufacturers face with product commercialization, patient access and adherence, and negotiating partnerships with pharmacy benefit managers (PBMs). He introduces us to EVERSANA DIRECT Commercialization, a direct-to-patient change/model. To learn more about EVERSANA DIRECT Commercialization and how the direct-to-patient model can help you, meet with EVERSANA at the Asembia Summit in Las Vegas

Pharmacy 98

Pharmacy Manufacturing Production Drugs 98

Pharmaceutical Technology

MARCH 18, 2025

Health Canada has granted approval for Biogens Skyclarys to treat Friedreichs ataxia (FA) in individuals aged 16 years and above.

237

237

Bio Pharma Dive

MARCH 17, 2025

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for its lead candidate.

Drugs 223

Drugs 223

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

Clinical Research

ACRP blog

MARCH 18, 2025

Consumers of popular culture in the 1960s and 1970s preferred their artificial intelligence (AI) to come with overtones of danger, if not outright world domination, judging by small- and large-screen science fiction artifacts ranging from episodes of the original Star Trek series to movies like 2001: A Space Odyssey and Colossus: The Forbin Project.

Clinical Research 69

Clinical Research Research Compliance Clinical Trials 69

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 19, 2025

The Indian Council of Medical Research (ICMR) is working to set up a Centre for Advanced Research in Aging, marking a significant move in India’s efforts to address the challenges of aging and age-related diseases.

Research 172

Research Marketing Clinical Trials Clinical Trials 172

Pharmaceutical Technology

MARCH 18, 2025

The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, with a notable acceleration in recent years.

Development 207

Development Drugs 207

Bio Pharma Dive

MARCH 20, 2025

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as Zolgensma, could be approved for a broad range of spinal muscular atrophy patients.

Gene Therapy 201

Gene Therapy Gene Drugs 201

Advertisement

Clinical Supply